{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:26:01Z","timestamp":1772803561493,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Current meningococcal prime-boost vaccination schedules include separate vaccines for serogroups ACWY and B. An investigational combined serogroups ABCWY vaccine (MenABCWY) was developed to protect against clinically important <jats:italic toggle=\"yes\">Neisseria meningitidis<\/jats:italic> serogroups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this phase 2, randomized, observer-blind, extension study (NCT01272180), participants 10\u201325 years of age received 1 booster dose of MenABCWY vaccine at 24 months (M) postprimary series of MenABCWY (2 doses), 4CMenB (2 doses) or MenACWY-CRM vaccine (1 dose). Immune responses to booster dose (1M postbooster) and antibody persistence (24M, 36M postprimary series) were assessed using bactericidal assay with human complement (hSBA). Reactogenicity and safety were evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>One hundred ninety participants were vaccinated. At 1M after the MenABCWY booster dose, seroresponse rates against serogroups ACWY ranged between 85% and 96%, 73% and 100% and 83% and 95% for participants previously receiving MenABCWY, 4CMenB and MenACWY-CRM, respectively. At 12M postbooster dose, \u226567% of participants across all groups had hSBA titers \u22658 for serogroups ACWY, except in 4CMenB-primed individuals for serogroup Y (45%). Across MenABCWY and 4CMenB-primed groups, hSBA titers \u22655 across serogroup B test strains were observed in 82%\u2013100% and 29%\u2013100% of participants at 1M and 12M postbooster, respectively. Geometric mean titers against serogroups ACWY increased from pre- to 1M postboosting with MenABCWY and persisted at 12M. The reactogenicity and safety profile of MenABCWY was similar to that of 4CMenB.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>MenABCWY may be suitable for prime-boost schedules against meningococcal disease, including regimens involving a primary series of either 4CMenB or MenACWY-CRM licensed vaccines.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001896","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T20:53:27Z","timestamp":1515790407000},"page":"475-482","source":"Crossref","is-referenced-by-count":22,"title":["Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines"],"prefix":"10.1097","volume":"37","author":[{"given":"Leszek","family":"Szenborn","sequence":"first","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan L.","family":"Block","sequence":"additional","affiliation":[{"name":"Kentucky Pediatric and Adult Research Inc, Bardstown, Kentucky"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Jackowska","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Centre of Postgraduate Medical Education, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryszard","family":"Konior","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Child Neurology, John Paul II Hospital, Krakow, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"GSK Vaccine, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Smolenov","sequence":"additional","affiliation":[{"name":"GSK Vaccine, Amsterdam, Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[{"name":"GSK Vaccine, Siena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo Anne","family":"Welsch","sequence":"additional","affiliation":[{"name":"GSK Vaccine, Rockville, MD."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11910-015-0524-6","article-title":"Invasive meningococcal disease in the 21st century\u2014an update for the clinician.","volume":"15","author":"Dwilow","year":"2015","journal-title":"Curr Neurol Neurosci Rep"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/649209","article-title":"Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease.","volume":"50","author":"Cohn","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40121-016-0107-0","article-title":"Meningococcal vaccinations.","volume":"5","author":"Crum-Cianflone","year":"2016","journal-title":"Infect Dis Ther"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1586\/14787210.2015.1070096","article-title":"Neisseria meningitidis infection: who, when and where?","volume":"13","author":"Gianchecchi","year":"2015","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 2","key":"R6-20230912","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease.","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease.","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"issue":"2 Suppl","key":"R8-20230912","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines.","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/cid\/ciu881","article-title":"Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales.","volume":"60","author":"Ladhani","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"184","DOI":"10.7326\/M15-3005","article-title":"Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older: United States, 2016.","volume":"164","author":"Kim","year":"2016","journal-title":"Ann Intern Med"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba\u00ae).","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad Med"},{"key":"R15-20230912","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/j.vaccine.2015.06.011","article-title":"Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.","volume":"33","author":"Nolan","year":"2015","journal-title":"Vaccine"},{"issue":"RR-2","key":"R16-20230912","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm6619a6","article-title":"Updated recommendations for use of MenB-FHbp serogroup B meningococcal vaccine - Advisory Committee on Immunization Practices, 2016.","volume":"66","author":"Patton","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus.","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.vaccine.2015.03.001","article-title":"A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial.","volume":"33","author":"Block","year":"2015","journal-title":"Vaccine"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/CVI.05028-11","article-title":"Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis.","volume":"18","author":"Mak","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2014.04.052","article-title":"The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.","volume":"32","author":"Idoko","year":"2014","journal-title":"Vaccine"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1097\/INF.0000000000000822","article-title":"Persistence of meningococcal antibodies and response to a third dose after a two-dose vaccination series with investigational MenABCWY vaccine formulations in adolescents.","volume":"34","author":"Saez-Llorens","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R28-20230912","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1080\/21645515.2015.1136040","article-title":"Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants.","volume":"12","author":"Baxter","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1097\/INF.0000000000000438","article-title":"Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.","volume":"33","author":"Baxter","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1097\/INF.0b013e318279ac38","article-title":"Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.","volume":"32","author":"Jacobson","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1080\/21645515.2015.1029686","article-title":"Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.","volume":"11","author":"Saez-Llorens","year":"2015","journal-title":"Hum Vaccin Immunother"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201805000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:36:32Z","timestamp":1694558192000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201805000-00025"}},"subtitle":["A Phase 2 Randomized Study"],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001896","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}